Physician profile
Robin Tsai
NPI 1386378255
$2,930.34
in general payments reported to CMS, 2019-2025
9 companies · $342 in 2025
The $342 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,561 · 2023: $140 · 2024: $887 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $687 · Food and Beverage: $682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $686.52 |
| Food and Beverage | $682.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Empire Medical, INC | $1,200.00 | 2022 | |
| Integra Lifesciences Corporation | $921.97 | 2024-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Medical Device Business Services, INC. | $243.00 | 2022 | |
| Orthofix Medical, INC. | $177.65 | 2025 | Physio-Stim, Tl-Hex Truelok Hexapod System |
| Amgen INC. | $121.83 | 2024 | Krystexxa |
| Smith+Nephew, INC. | $121.81 | 2023 | Stravix, Grafix, Oasis |
| Horizon Therapeutics Plc | $118.46 | 2022 | |
| Averitas Pharma INC. | $17.93 | 2023 | Qutenza |
| Kerecis Limited | $7.69 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.